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Abstract: Erythropoietin (EPO) has been demonstrated the ability of recombinant human erythropoietin (r-Hu-EPO), 
when administered intracerebro-ventricularly, to improve stroke outcome through the reduction of stroke damage. In a brain 
ischemic model, however, systemic administration of r-Hu-EPO has not been intensely investigated given that in general, large 
glycosylated molecules have been deemed incapable of crossing the blood-brain barrier. In this study, administration of r-Hu-
EPO for 4 days, intraperitoneally aft  er ischemia-reperfusion (I-R) increased the number of bromodeoxyuridine (BrdU)-positive 
cells in the penumbra (10.1±1.4, n=5, P<0.05) and in the subventricular zone (SVZ) of the lateral ventricle (LV) (25±2.7, n=5, 
P<0.05) as compared with those of I-R (penumbra: 2.5±0.7; SVZ of LV: 3.8±1.5). A signifi  cant increase of BrdU-positive cells 
in these areas was coincident with a strong immunoreactivity of oligodendrocyte progenitor cell marker (2', 3'-cyclic nucleotide 
3'-phosphodiesterase). Furthermore, r-Hu-EPO administration increased the number of BrdU-positive cells in the choroid 
plexus (7.8±2.3, n=5, P<0.05) and in cerebral blood vessels (3.5±1.3, n=5, P<0.05) when compared with those of I-R (choroid 
plexus: 1.2±0.5; cerebral blood vessels: 0.6±0.1). Th   ese results suggest that, even when systemically administered, r-Hu-EPO 
may have therapeutic potential for stroke via the proliferation of oligodendroglial and endothelial progenitor cells.
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acute administration of recombinant human erythropoietin 
(r-Hu-EPO) in a rat model of spinal cord injury reduces the 
lesion size, attenuates gliosis and microglial/macrophage 
activation, enhances myelinogenesis and improves loco-
motor outcome. In addition, Kadota et al. (2009) reported 
that continuous low dose infusion of EPO exerted neuro-
protective/rescue effects with neurogenic potential in a rat 
Parkinsonian model. 
It has been demonstrated that focal ischemic injury 
stimulates progenitor proliferation and increases the size 
of the adult rodent forebrain subventricular zone (SVZ) 
of the lateral ventricle (LV) (Arvidsson et al., 2002; Parent 
et al., 2002). Further, Wang et al. (2004) reported that 
Introduction
Erythropoietin (EPO) was first described as a cytokine 
which acted as a major regulator of erythropoiesis (Moritz et 
al., 1997). However, the biological role of EPO is not limited 
only to haematopoiesis (Digicaylioglu et al., 1995; Morishita 
et al., 1997). Vitellaro-Zuccarello et al. (2008) described that Proliferation of progenitors for erythropoietin in 
the ischemic brain
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intracerebroventrically injected EPO enhanced neurogenesis 
in the SVZ of the LV aft  er stroke in the adult rodent. However, 
other studies have reported depletion of neuronal stem cells in 
the SVZ aft  er hypoxia-ischemia (Levison et al., 2001; Skoff   et 
al., 2001). Additionally, neuronal and/or astroglial progenitors 
also reside in the subgranular zone (SGZ) of the dentate 
gyrus (DG) in the hippocampal formation (Gage et al., 1998). 
Despite strong evidence for the neuroprotective benefits of 
EPO in the treatment of acute stroke (Sakanaka et al., 1998; 
Sirén et al., 2001), it is unclear whether the neuroprotective 
eff  ects of EPO mediate proliferation of neuronal and/or glial 
progenitor cells in germinative areas such as the SVZ of the 
LV and the SGZ of the DG. Moreover, the neuroprotective 
mechanism of systemically (intraperitoneally) administered 
EPO remains poorly understood. 
Cultivated mature endothelial cells also express EPO 
and erythropoietin receptor (EPOR) and endothelial cell 
proliferation has been shown to be induced by EPO (Vogel 
et al., 1997). In practical, endothelial cells and hematopoietic 
cells are believed to be derived from the same mesenchymal 
precusor, the so called hemangioblast. Th   is may explain why 
endothelial cells carry the EPOR and can be stimulated by 
EPO (Marti et al., 2000). However, there has been a lack of 
reports regarding endothelial proliferation in the ischemic 
rat brain under EPO treatment despite the fact that neuronal/
glial proliferation and angiogenesis is known to be coupled in 
the brain and that both are cooperative in the treatment of the 
ischemic brain (Leventhal et al., 1999; Kim et al., 2009).
The present study sought out to explore the potential for 
the proliferation of neuronal/glial and endothelial progenitor 
cells after ischemia-reperfusion (I-R) in subjects treated 
intraperitoneally with r-Hu-EPO. We selected a model of 
I-R for this study rather than one of permanent ischemia 
because it more closely mimicked the clinical situation of an 
acute cerebral infarction with early reperfusion, producing a 
necrotic core surrounded by a substantial penumbra.
Materials and Methods
Reagents
Th   e r-Hu-EPO (Epoetin beta, 2000 IU/UI/0.3 ml, Roche) 
used was a human 165-aa glycoprotein manufactured using 
recombinant DNA technology and containing the identical 
amino acid sequence to isolated natural EPO as well the same 
biological activity (Egrie et al., 1986; Pardridge 1997). R-Hu-
EPO is approximately 80% homologous to rodent EPO, and 
it has been shown to be biologically active in rodents for 
erythropoietic as well as neurotrophic functions. Although 
an immune response against human antigens can be elicited 
in rodents, it requires several weeks to obtain even a weak 
response and thus is not important in the context of these 
short-term studies. All experiments were performed by 
using r-Hu-EPO, which was formulated as a sterile, colorless 
liquid in isotonic sodium chloride/sodium citrate or sodium 
chloride/ sodium phosphate buff  ered saline (PBS) with 1.25% 
human albumin. 
Induction of I-R
Studies were carried out in 9-week-old male Sprague-
Dawley rats (250~280 g, n=13) each having access to 
drinking water and standard rodent food pellets ad libitum. 
All experimental protocols were reviewed and approved by 
the Animal Care and Use Committee of Dongguk University 
(IRB: 09~35). Animal care and use were in accordance with 
the guidelines of the National Institutes of Health (Bethesda, 
MD). 
Focal cerebral I-R was induced by occlusion of the left 
middle cerebral artery as described previously (Hasegawa et 
al., 1994). Briefl  y, anesthesia was induced with 3% isofl  urane 
in a mixture of oxygen/nitrous oxide (30 : 70), and rats were 
maintained with 1% isoflurane in the oxygen/nitrous oxide 
gas mixture. A catheter was inserted and positioned in the 
femoral artery. Arterial blood pressure was measured and 
recorded continuously throughout the procedure, and body 
temperature was maintained between 36.5
oC and 37.0
oC with 
the aid of a heating pad and heating lamp. The left middle 
cerebral artery was occluded using a 4~0 mono fi  lament (3 
cm in length) coated with a mixture of silicone resin. For 
reperfusion, the nylon filament was withdrawn 2 h after 
middle cerebral artery occlusion (MCAO) and then perfused 
for 14 days. 
EPO and BrdU treatment aft  er I-R 
To examine whether treatment with systemically 
administered r-Hu-EPO stimulated the proliferation of 
neural and endothelial progenitor cells in the ischemic brain, 
r-Hu-EPO at a dose of 5,000 units/kg was intraperitoneally 
injected daily for 4 days into rats, starting reperfusion after 
MCAO. Doses of r-Hu-EPO were selected based on previous 
studies (Sirén et al., 2001; Calvillo et al., 2003). To achieve 
labeling of proliferating cells, bromodeoxyuridine (BrdU, Anat Cell Biol 43:140~149, 2010 Young Jae Kim and Yong-Wook Jung 142
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100 mg/kg, Sigma Aldrich Corp., St Louis, MO, USA) was 
injected intraperitoneally daily for 4 days into rats starting 10 
days after reperfusion. After completing the I-R protocols, 
animals were anesthetized with isoflurane and the brains 
were removed and subject to 2% 2,3,5-triphenyltetrazolium 
chloride (TTC: sigma Aldrich Corp., St Louis, MO, USA) 
staining and immunohistochemical studies.
TTC staining of infarction
Rats (n=3) were killed and their brains were quickly 
removed and sectioned into 2-mm-thick slices starting 
at the frontal pole using a Brain Matrix Slicer (Vibratome 
Co.). Slices were then immersed in TTC in a petri-dish 
and incubated at 37
oC for 20 minutes. Slices were fl  ipped at 
the 10-minute mark for consistent staining of anterior and 
posterior faces and then scanned using an Epson perfection 
1,200 U scanner and Adobe Photoshop soft  ware. 
Tissue processing
The brains from the I-R (n=5) and EPO-treated I-R 
rats (n=5) were fixed with a transcardiac infusion of 4% 
paraformaldehyde and post-fixed in the same fixative for 
12 h. Perfused brains were then paraffin-embedded and 5 
μm thick serial coronal sections were obtained at the level 
of dorsal third ventricle (bregma -2.30 mm). Paraffin wax 
was removed in xylene over night at room temperature (RT) 
and the sections were rehydrated with ethanol (99%, 96%, 
70%). Aft  er washing in distilled water, the sections were then 
stained using a DAKO kit for immunohistochemistry.
Pretreatment for BrdU immunohisochemistry
After washing in distilled water, the sections were then 
incubated in 50% formamide/2XSSC buff  er (0.3M NaCl/ 0.03 
M sodium citrate) at 65
oC for 2 h, rinsed in 2XSSC, incubated 
in 2 M HCl for 30 min, and rinsed in 0.1 M borate buff  er pH 
8.5 for 10 minutes. 
Immunohistochemistry
Following deparaffinization, sections were stained with 
a DAKO kit. Endogenous peroxidase activity was blocked 
by 5-min incubation in 3.0% H2O2. After washing in PBS, 
the sections were reacted with rat anti-BrdU (Sigma, St. 
Louis, Mo, USA, 1 : 100), rat anti-neuronal nuclei (NeuN) 
monoclonal antibody (Chemicon, Temecula, CA, USA, 1 : 
100), rat anti-glial fi  brillary acidic protein (GFAP) monoclonal 
antibody (Boehringer, Mannheim, Germany, 1 : 200), rat 
anti-2', 3'-cyclic nucleotide 3'-phosphodiesterase monoclonal 
antibody (CNPase) (Chemicon, Temecula, CA, USA, 1: 
100) for 16~18 h at 4
oC, and consequently with biotinylated 
universal anti-mouse, -goat, and -rabbit immunoglobulins 
in PBS for 30 min. After washing in PBS, the sections were 
incubated with streptoavidin conjugated to horseradish 
peroxidase (HRP) in PBS for 30 min. Finally, the sections 
were reacted with a solution containing diaminobenzidine 
(DAB) and hydrogen peroxide (0.001%). The sections were 
then counterstained with Mayer's hematoxylin to visualize 
cell nuclei. BrdU-positive cells in each group of 5 animals 
were observed at the level of bregma -2.30 mm. At least 
five brain sections from each group were observed under 
20X magnifi  cation fi  eld. All BrdU-positive cell counting was 
performed in a blind and randomized manner. Values were 
presented as means±SE. Comparisons between groups were 
made using un-paired Student t-test and P values less than 
0.05 were considered signifi  cant. Quantifi  cation of the relative 
optical density of the immunoreactivity for NeuN, GFAP and 
CNPase was performed using Scion Image soft  ware (version 
1.59).
Results
Establishment of I-R 
In agreement with a previous study (Yan et al., 2001), 
extensive infarction was detected in the frontal and parietal 
cortical and subcortical areas, including the basal ganglia, 
over a series of brain sections after I-R. However, r-Hu-
EPO treatment aft  er I-R did not aff  ect the infarction size as 
compared with that of I-R (data not shown). 
Enhancement of progenitor cells in ischemic penum-
bra and SVZ of LV treated with r-Hu-EPO
I, P, and C in the rectangles from Fig. 1A indicate 
infarction, penumbra, and the contralateral cortical area. 
R-Hu-EPO treatment after I-R increased the number 
of BrdU-positive cells in the penumbra (10.1±1.4, n=5, 
P<0.05) compared with that of I-R (2.5±0.7, n=5) (Fig. 
1C). However, treatment with r-Hu-EPO did not increase 
the numbers of BrdU positive cells in the infarction area or 
contralateral non-ischemic cortex compared with that of 
the penumbra even though both showed altered neuronal 
morphology (Figs. 1B and D). Black and white arrows from 
Fig. 2A indicate penumbra and infarction cortical areas. Proliferation of progenitors for erythropoietin in 
the ischemic brain
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In contrast to infarction area, large amount of NeuN- and 
GFAP- immunoreactive cells in the penumbra were remained 
after I-R (Figs. 2B and C, I-R). The immunoreactivity 
of CNPase was almost faded in the penumbra as well as 
infarction area after I-R (Fig. 2D, I-R). In the penumbra, 
the immunoreactivity of NeuN and GFAP was unchanged 
after r-Hu-EPO treatment (Figs. 2B and C, I-R+EPO). 
However, the immunoreactivity of CNPase in the penumbra 
was strongly expressed after treatment with r-Hu-EPO as 
compared with that of I-R (Fig. 2D, I-R+EPO). Th  e  rectangle 
in Fig. 3A indicates the ipsilateral LV. Th   ere was a signifi  cant 
increase in BrdU-positive cells in the ipsilateral SVZ of the LV 
after r-Hu-EPO treatment (25±2.7, n=5, P<0.05) compared 
with that of the I-R (3.8±1.5, n=5) (Fig. 3B, I-R+EPO). Th  e 
immunoreactivity of NeuN and GFAP in the ipsilateral SVZ 
of the LV after r-Hu-EPO treatment was not significantly 
different from the I-R (data not shown). However, a strong 
increase in immunoreactivity of CNPase was detected in 
the ipsilateral SVZ of the LV after r-Hu-EPO treatment as 
compared with that of I-R (Fig. 3C, I-R+EPO). In the SGZ of 
the DG, r-Hu-EPO treatment did not increase the number of 
BrdU-positive cells in the upper and lower blade as compared 
with that of LV (data not shown). The increased number 
of BrdU-positive cells and dense labeling of CNPase in the 
penumbra and SVZ of the LV aft  er r-Hu-EPO treatment are 
increasing the possibility that EPO selectively enhances the 
proliferation of oligodendrocyte progenitor cells (OPCs).
Enhancement of endothelial cell proliferation in 
ischemic brains treated with r-Hu-EPO
The letters B, C, D, and E in the rectangles indicates 
alphabetical numbers of panels (Fig. 4A). Panel B and 
Fig. 1. Immunohistochemical staining of bromodeoxyuridine (BrdU)-positive cells after ischemia-reperfusion (I-R) and I-R with r-Hu-EPO 
treatment (I-R+EPO) in the rat brain. (A) 2,3,5-triphenyltetrazolium chloride (TTC) staining of brain slices at bregma -2.30 mm aft  er I-R. 
Th   e rectangles indicate the infarction area I, ischemic penumbra P, and contralateral non-ischemic cortex C. (B~D) Treatment with r-Hu-EPO 
aft  er I-R did not increase the number of BrdU-positive cells in the infarction and contralateral non-ischemic areas (B, D, I-R+EPO). However, 
the number of BrdU-positive cells in the ischemic penumbra of I-R+EPO rat brain was increased compared with that of the I-R (C, I-R+EPO, 
arrows). Scale bar, 50 μm.Anat Cell Biol 43:140~149, 2010 Young Jae Kim and Yong-Wook Jung 144
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C indicate the locations of the choroid plexus (CP) and 
capillary plexus of third ventricle (CP-TV) while panel D 
and E indicate the locations of the pia mater (PM) and blood 
vessels in the hippocampus. Treatment with r-Hu-EPO 
aft  er I-R increased the number of BrdU-positive cells in the 
endothelial cells of the CP (7.8±2.3, n=5, P<0.05) and CP-TV 
(15.5±2.4, n=5, P<0.05) compared with those of the I-R (CP: 
1.2±0.5; CP-TV: 4.8±1.3, n=5, respectively) (Figs. 4B and C). 
A signifi  cant increase of BrdU-positive cells in the I-R treated 
with r-Hu-EPO was also detected in the endothelial cells of 
the PM (10.5±2.1, n=5, P<0.05) compared with that of the 
I-R (3.2±1.2, n=5) (Fig. 4D). Furthermore, the number of 
BrdU-positive cells in the blood vessels of the hippocampus 
increased after r-Hu-EPO treatment (3.5±1.3, n=5, P<0.05) 
compared with that of the I-R (0.6 ± 0.1, n=5) (Fig. 4E).
Discussion
Intraperitoneal injection of r-Hu-EPO following I-R
Central and systemic EPO systems are separate, a concept 
which has been further reinforced by the impermeability 
of the blood brain barrier (BBB) to most plasma proteins. 
However, recent studies have reported that r-Hu-EPO, 
systemically injected into rats subjected to kainate-induced 
seizures, may be able to cross the BBB using receptor-
Fig. 2. Immunohistochemical staining of neuronal nuclei (NeuN), glial fibrillary acidic protein (GFAP), and 2', 3'-cyclic nucleotide 3'- 
phosphodiesterase (CNPase) in infarction and penumbra areas aft  er I-R and I-R+EPO. (A) TTC staining of brain slices at bregma -2.30 mm aft  er 
I-R. White and black arrows indicate infarction and penumbra areas. Th   ere were not seen NeuN-, GFAP-, and CNPae-immunoreactive cells in the 
infarction areas aft  er I-R and I-R+EPO (B~D). Th   e numbers of NeuN- and GFAP-immunoreactive cells in the penumbra of the I-R+EPO were 
not changed compared with those of I-R (B, C, I-R+EPO). However, CNPase-immunoreactive cells in the penumbra were increased under the 
treatment with r-Hu-EPO aft  er I-R compared with that of I-R (D, I-R+EPO). Scale bar, 50 μm. Proliferation of progenitors for erythropoietin in 
the ischemic brain
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dependent endocytosis followed by translocation into 
the brain (Brines et al., 2000; Grasso et al., 2002), thereby 
lessening seizure severity, elongate seizure latencies, and 
reduce neuronal damage (Brines et al., 2000). Th   e data in the 
present study has demonstrated that systemic administration 
of r-Hu-EPO is also eff  ective in stimulating the proliferative 
potentials of progenitor cells in the ischemic penumbra and 
SVZ of LV in a similar fashion to intracerebro-ventriculaly 
administered EPO. Marti et al. (2000) suggested the mecha-
nism of eff  ectiveness of systemically administered EPO in the 
ischemic brain, whereby ischemia produces leaks in the BBB 
and therefore brain cells are able to easily access blood-borne 
EPO in ischemic infarcted areas. 
Increased oligodendrocyte progenitor cells in the I-R 
brain treated with r-Hu-EPO
Our data indicate that systemic administration of r-Hu-
EPO after I-R significantly increased progenitors, especially 
in the penumbra. However, the contralateral cortex and 
infarction area did not show a similar increase. EPO is 
required for normal brain development and regulates 
neurogenesis and glial cell proliferation in the adult mouse 
brain (Shingo et al., 2001; Sugawa et al., 2002), whereas stroke 
up-regulates endogenous EPO and its receptor (Bernaudin 
et al., 1999). Thus, our data suggest the possibility that 
proliferation of progenitors in the penumbra was due to the 
selective increase of endogenous EPO in the penumbra in 
addition to the systemically administered r-Hu-EPO.
Progenitor cells that reside in the adult SVZ of the LV 
Bregma: 2.30  mm -
A
C
B
Fig. 3. Immunohistochemical staining 
of BrdU-positive cells in the sub  -
ventricular zone (SVZ) of the late  ral 
ventricle (LV) after I-R and I-R+ 
EPO. (A) TTC staining of brain 
slices at bregma -2.30 mm after I-R. 
The rectangle indicates the ipsilateral 
LV. BrdU-positive cells in the ipsila-
teral SVZ of the LV under r-Hu-
EPO treatment following I-R were 
significantly increased (B, I-R+EPO, 
arrows) compared with that of I-R. 
Immunohistochemical staining for 
CNPase in the ipsilateral SVZ of the LV 
was increased in the r-Hu-EPO treated 
ischemic rat as compared with that of 
I-R (C, I-R+EPO). Scale bar, 50 μm. Anat Cell Biol 43:140~149, 2010 Young Jae Kim and Yong-Wook Jung 146
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include a subpopulation of cells that exhibit the fundamental 
properties of neural stem cells: long-term self-renewal and 
multipotentiality (Potten & Loeffl   er, 1990; Weiss et al., 1996) 
whereas the progenitor cells that reside in the SGZ of the 
adult DG exhibit less self-renewal ability and unipotentiality 
(Kuhn et al., 1996; Weiss et al., 1996; Palmer et al., 2000). 
Fig. 4. Immunohistochemical staining of BrdU-positive cells in the endothelium of the choroid plexus (CP), capillary plexus of the third ventricle 
(CP-TV), pia mater (PM), and blood vessels of the hippocampus aft  er I-R and I-R+EPO treatment. (A) TTC staining of brain slices at bregma 
-2.30 mm aft  er I-R. B to E in the rectangle indicates the label for each panel. (B~E) A few BrdU-positive cells were found in endothelial cells 
of the CP-TV and PM aft  er I-R (C, D, I-R, arrows). Treatment with r-Hu-EPO signifi  cantly increased the number of BrdU-positive cells in the 
CP and CP-TV compared with those of I-R (B, C). BrdU-positive cells in the PM of the ischemic cortex under r-Hu-EPO treatment increased 
compared with that of I-R (D). In the hippocampus, the numbers of BrdU-positive cells in the blood vessels under r-Hu-EPO treatment increased 
compared with that of I-R (E). Scale bar, 50 μm.Proliferation of progenitors for erythropoietin in 
the ischemic brain
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Furthermore, focal cerebral ischemia induced significant 
increases in numbers of BrdU labeled cells in the ipsilateral 
cortex, subcortex, SVZ and olfactory bulb in contrast to global 
ischemia, which induced in BrdU cells only in the DG (Liu 
et al., 1998). Th   erefore, a selective increase of BrdU-positive 
cells in the SVZ of the LV indicates that r-Hu-EPO exhibit 
distinct profiles of cellular proliferation to specific regional 
progenitors depending on the type of ischemia. 
The result of present study also showed that increased 
BrdU-positive cells in ischemic penumbra and SVZ of the 
LV in r-Hu-EPO-treated ischemic rats are associated with 
significantly increased CNPase-immunoreactive cells which 
are identified as OPCs (Ness et al., 2005). CNPase is found 
almost exclusively in oligodendrocytes lineage cells, the 
cells that form myelin in the central nervous system. This 
finding is in line with previous observations showing that 
systemic delivery of r-Hu-EPO in an experimental model 
of autoimmune encephalomyelitis decreases demyelination 
and increases integral membrane proteoglycan NG2-positive 
OPCs (Zhang et al., 2005). Since OPCs are able to diff  erentiate 
in myelinating oligodendrocytes both in vitro (Shi et al., 1998) 
and in vivo (Bu et al., 2004), their enhanced proliferation 
likely contributes to the restoration of oligodendrocyte. If the 
increased immunoreactivity of CNPase means the enhanced 
numbers of OPCs, increased OPCs may be benefi  cial because 
these cells express the excitatory amino acid cotransporter 1 
and are consequently involved in the removal of the excess of 
the neurotransmitter from the extracellular space (Gottlieb 
et al., 2000), thus limiting its neurotoxic effects (Profyris et 
al., 2004). However, it remains unclear that enhanced OPCs 
in the penumbra and SVZ of the LV of the ischemic brain 
integrate into the infarcted cortical architecture and/or 
improve the pathological and/or neurological changes.
Increased endothelial cell proliferation in the I-R 
brain treated with r-Hu-EPO
Th   e present data demonstrated that treatment with r-Hu-
EPO increased the BrdU-positive cells in the CP, CP-TV, PM, 
and blood vessels in the hippocampus following I-R which 
means r-Hu-EPO strongly augments angiogenesis in the 
ischemic brain. EPO has been shown to induce proangiogenic 
eff  ects in cultivated endothelial cells and in the chick embryo 
chorioallantoic membrane assay (Carlini et al., 1995; Ribatti 
et al., 1999). Recently, other studies demonstrated that 
EPO not only affected mature endothelial cells in postnatal 
neovascularization, but also profoundly increased the number 
of circulating endothelial progenitor cells by mobilizing 
bone marrow-derived hematopoietic stem cells (Asahara 
et al., 1999; Takahashi et al., 1999). In addition, as in the 
case with erythroid precusor cells, EPO also seemed to be a 
survival factor for endothelial cells through the prevention 
of cell injury and DNA fragmentation by activating AKT1 
and inhibiting cytochrome c release and caspase activity 
(Chong et al., 2002). Therefore, systemically administered 
r-Hu-EPO might contribute to increased angiogenesis as 
well as to reduced vascular damage after I-R. However, it 
is still unclear as to whether increased angiogenesis and 
reduced vascular damage in blood vessels of the ischemic 
brain can recover the vessels’ barrier function given that the 
reduction of oxygen supply (ischemic stress), as well as post-
ischemia reoxygenation, clearly induced profound alterations 
in the cytoskeleton organization in vascular endothelial cells 
(Crawford et al., 1996). 
Angiogenesis and proliferation of OPCs are linked in the 
adult brain via vascular endothelial growth factor (VEGF) 
and brain derived neurotrophic factor (BDNF) (Zhang et al., 
2000). Administration of r-Hu-EPO increased VEGF levels 
in the ischemic penumbra, which was able to block using 
SU1498, a specifi  c VEGF receptor 2 antagonist (Wang et al., 
2004). In addition, cerebral endothelial cells express EPOR 
which may represent targets for intraperitoneal administration 
of r-Hu-EPO. Further, increased endothelial cells produce 
more BDNF that enhances oligodendrocyte proliferation and 
diff  erentiation (Pincus et al., 1998; Girard et al., 2005; Zhang 
et al., 2006). Th   erefore, our data suggest that r-Hu-EPO may 
act directly on cerebral endothelial cells that secrete more and 
more VEGF and BDNF thereby, accelerating angiogenesis 
and the production of OPCs via a paracrine pathway. 
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